Skip to page body Patient Care Survivorship Research Cancer Types News Giving Community Partners Clinical Trials
UCLA's Jonsson Comprehensive Cancer Center
Take the Jonsson Cancer Center Site Survey

JCCC Member Directory

Steven Wong, M.D.
Steven Wong, M.D.

Specialty:

Hematology and Oncology

General Information:

Gender:
Male
Language(s):
English

Affiliation(s):

Associate Clinical Professor, Department of Medicine, Hematology/Oncology
Member, JCCC Signal Transduction and Therapeutics Program Area

Hospital Affiliation(s):

Ronald Reagan UCLA Medical Center
UCLA Medical Center, Santa Monica

Education:

Fellowship:
Medical Oncology Research, UCLA School of Medicine, 1999 - 2002
Hematology-Oncology, UCLA School of Medicine, 1996 - 1999
Residency:
Internal Medicine, UCLA School of Medicine, 1994 - 1996
Internship:
Internal Medicine, UCLA School of Medicine, 1993 - 1994
Medical Degree:
M.D., UCLA School of Medicine, 1993

Contact Information:

Phone:
(310) 206-6909 Westwood
(310) 829-5471 Santa Monica
Email:

Practice Information:

Clinical Interest(s):
Adrenal cancer-metastasis
Advanced malignancies
Bladder cancer-metastasis
Breast cancer
Gastrointestinal cancer
General oncology
Genitourinary
Gynecologic oncology
Head and neck oncology
Ovarian cancer
Prostate cancer
Renal cancer
Testicular cancer-metastasis

Scientific Interest(s):

Dr. Steven Wong has been engaged in translational oncology research at UCLA since 1985. He currently engages in translational research in solid tumor oncology.

Selected Cancer-Related Publications:

Ather F, Hamidi H, Fejzo MS, Letrent S, Finn RS, Kabbinavar F, Head C, Wong SG. Dacomitinib, an irreversible Pan-ErbB inhibitor significantly abrogates growth in head and neck cancer models that exhibit low response to cetuximab. PLoS One. 2013;8(2):e56112. doi: 10.1371/journal.pone.0056112. Epub 2013 Feb 6.

Klatte T, Seligson DB, Rao JY, Yu H, de Martino M, Garraway I, Wong SG, Belldegrun AS, Pantuck AJ. Absent CD44v6 expression is an independent predictor of poor urothelial bladder cancer outcome. J Urol. 2010 Jun;183(6):2403-8. doi: 10.1016/j.juro.2010.01.064. Epub 2010 Apr 18.

Soon PS, Tacon LJ, Gill AJ, Bambach CP, Sywak MS, Campbell PR, Yeh MW, Wong SG, Clifton-Bligh RJ, Robinson BG, Sidhu SB. miR-195 and miR-483-5p Identified as Predictors of Poor Prognosis in Adrenocortical Cancer. Clin Cancer Res. 2009 Dec 15;15(24):7684-7692. Epub.

Britten CD, Finn RS, Bosserman LD, Wong SG, Press MF, Malik M, Lum BL, Slamon DJ. A phase I/II trial of trastuzumab plus erlotinib in metastatic HER2-positive breast cancer: a dual ErbB targeted approach. Clin Breast Cancer. 2009 Feb;9(1):16-22. doi: 10.3816/CBC.2009.n.003.

Klatte T, Seligson DB, Rao JY, Yu H, de Martino M, Kawaoka K, Wong SG, Belldegrun AS, Pantuck AJ. Carbonic anhydrase IX in bladder cancer: a diagnostic, prognostic, and therapeutic molecular marker. Cancer. 2009 Apr 1;115(7):1448-58. doi: 10.1002/cncr.24163.